Antibodies to topoisomerase II in idiopathic pulmonary fibrosis.
Antibodies to DNA topoisomerase II (anti-topoisomerase II) were detected by ELISA in the sera of 18 out of 41 (44%) patients with idiopathic pulmonary fibrosis (IPF). Follow-up sera were also obtained from 19 of the patients. DNA topoisomerase II binding remained constantly high or low in the majority of follow-up sera, but 2 out of the 8 positive cases became negative while 3 out of the 11 negative cases became positive during follow-up. No association was found between occurrence of anti-topoisomerase II antibodies and any indices of disease severity. Furthermore, individual patient follow-up did not show any correlation between changes in topoisomerase II binding and deterioration or improvement of clinical status. In conclusion our study shows that although anti-topoisomerase II are detectable in a large fraction (approximately 50%) of IPF patients and are useful for diagnostic purposes, they do not provide a measure of clinical activity.
Meliconi
R
R
Patologia Medica I, Policlinico S. Orsola, Bologna, Italy.
Negri
C
C
Borzì
R M
RM
Facchini
A
A
Sturani
C
C
Fasano
L
L
Fabbri
M
M
Astaldi Ricotti
G C
GC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000032:analysis*; D004250:DNA Topoisomerases, Type II / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000276:immunology* / Q000503:physiopathology; D012720:Severity of Illness Index
D000906:Antibodies; D004250:DNA Topoisomerases, Type II